Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

myRocky vs Tell Her Doc

myRocky
Graded #487

Lower grade

vs+6
Tell Her Doc
Graded #400

Higher grade

The verdict

Tell Her Doc takes it — 57.4/100 to 51.4/100.

Tell Her Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tell Her Doc is a women-focused, self-pay telehealth program for compounded GLP-1 weight loss — compounded semaglutide and tirzepatide in injection, oral, and orally-dissolving-tablet forms, plus microdoses.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuemyRocky +6
34
28
Dose & formulationTell Her Doc +10
53
63
Clinical oversightTell Her Doc +12
64
76
Labs & monitoringEven
52
52
FulfillmentTell Her Doc +13
70
83
Contract termsTell Her Doc +20
41
61
myRocky · left barTell Her Doc · right bar

The numbers

MetricmyRockyTell Her Doc
WeighScore51.4/10057.4/100
GradeCC
Scorecard rank#487#400
SemaglutideNot disclosed$269/mo (microdose tier, plus a separate fee, compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
myRocky

Graded #487 · C

Strengths

  • Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
  • LegitScript Approved
  • 42-state coverage with an 8-state expansion roadmap published
  • Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription

Where it loses points

  • Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
  • Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
  • Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
  • Brand-only — no compounded option for cost-sensitive patients
  • $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Tell Her Doc

Graded #400 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

Where it loses points

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard